M&A

Market Access
calendar

Is pharma market on the rebound in 2023?

As the financial markets have been roiled by inflation and a minor banking crisis, the pharma industry experienced a period where M&A largely disappeared and investment into biotechs dr

News
Novo Nordisk buys another obesity biotech

Novo Nordisk buys another obesity biotech

Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 milli